Insider Transactions in Q4 2017 at Crispr Therapeutics Ag (CRSP)
Insider Transaction List (Q4 2017)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 29
2017
|
Tyler Dylan Hyde Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
30,300
-6.38%
|
$666,600
$22.49 P/Share
|
|
Dec 29
2017
|
Tyler Dylan Hyde Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,300
+5.84%
|
$198,900
$13.5 P/Share
|
|
Dec 28
2017
|
Tyler Dylan Hyde Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
700
-0.6%
|
$14,700
$21.75 P/Share
|
|
Dec 28
2017
|
Tyler Dylan Hyde Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
700
+0.6%
|
$9,800
$14.43 P/Share
|
|
Dec 22
2017
|
Thomas Woiwode Director |
SELL
Open market or private sale
|
Direct |
3,059
-38.15%
|
$61,180
$20.29 P/Share
|
|
Dec 22
2017
|
Bradley J Ph D Bolzon Director |
SELL
Open market or private sale
|
Direct |
26,016
-48.41%
|
$520,320
$20.3 P/Share
|
|
Dec 22
2017
|
Tyler Dylan Hyde Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
15,000
-11.52%
|
$300,000
$20.55 P/Share
|
|
Dec 21
2017
|
Samarth Kulkarni Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+9.17%
|
$15,000
$1.81 P/Share
|
|
Dec 15
2017
|
Tyler Dylan Hyde Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
15,000
-10.33%
|
$270,000
$18.9 P/Share
|
|
Dec 04
2017
|
Celgene Corp /De/ > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
30,485
-0.81%
|
$579,215
$19.47 P/Share
|
|
Dec 01
2017
|
Celgene Corp /De/ > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
87,991
-2.29%
|
$1,671,829
$19.1 P/Share
|
|
Dec 01
2017
|
Samarth Kulkarni Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
26,667
+16.64%
|
$506,673
$19.12 P/Share
|
|
Nov 30
2017
|
Celgene Corp /De/ > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
12,666
-0.33%
|
$240,654
$19.04 P/Share
|
|
Nov 29
2017
|
Celgene Corp /De/ > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
4,263
-0.11%
|
$80,997
$19.25 P/Share
|
|
Nov 28
2017
|
Celgene Corp /De/ > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
5,080
-0.13%
|
$96,520
$19.22 P/Share
|
|
Nov 27
2017
|
Celgene Corp /De/ > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
27,990
-0.72%
|
$531,810
$19.75 P/Share
|
|
Nov 27
2017
|
Bradley J Ph D Bolzon Director |
SELL
Open market or private sale
|
Direct |
200
-0.37%
|
$4,000
$20.24 P/Share
|
|
Nov 27
2017
|
Thomas Woiwode Director |
SELL
Open market or private sale
|
Direct |
200
-2.43%
|
$4,000
$20.24 P/Share
|
|
Nov 24
2017
|
Celgene Corp /De/ > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
26,010
-0.66%
|
$520,200
$20.0 P/Share
|
|
Nov 24
2017
|
Bradley J Ph D Bolzon Director |
SELL
Open market or private sale
|
Direct |
1,507
-2.72%
|
$30,140
$20.21 P/Share
|
|
Nov 24
2017
|
Thomas Woiwode Director |
SELL
Open market or private sale
|
Direct |
1,700
-17.14%
|
$34,000
$20.21 P/Share
|
|
Nov 22
2017
|
Celgene Corp /De/ > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
256,000
-6.13%
|
$4,864,000
$19.76 P/Share
|
|
Nov 20
2017
|
Celgene Corp /De/ > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
158,718
-3.6%
|
$3,015,642
$19.02 P/Share
|
|
Nov 17
2017
|
Celgene Corp /De/ > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
51,282
-1.15%
|
$923,076
$18.44 P/Share
|
|
Nov 16
2017
|
Celgene Corp /De/ > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
105,000
-2.3%
|
$1,890,000
$18.39 P/Share
|
|
Nov 15
2017
|
Celgene Corp /De/ > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
15,000
-0.33%
|
$255,000
$17.67 P/Share
|
|
Nov 14
2017
|
Celgene Corp /De/ > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
14,907
-0.32%
|
$253,419
$17.19 P/Share
|
|
Nov 13
2017
|
Celgene Corp /De/ > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
65,093
-1.4%
|
$1,106,581
$17.76 P/Share
|
|
Nov 10
2017
|
Celgene Corp /De/ > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
10,000
-0.21%
|
$170,000
$17.28 P/Share
|
|
Nov 09
2017
|
Celgene Corp /De/ > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
20,000
-0.43%
|
$340,000
$17.08 P/Share
|
|
Nov 08
2017
|
Celgene Corp /De/ > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
16,875
-0.36%
|
$303,750
$18.06 P/Share
|
|
Nov 07
2017
|
Celgene Corp /De/ > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
23,000
-0.49%
|
$414,000
$18.54 P/Share
|
|
Nov 06
2017
|
Celgene Corp /De/ > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
79,327
-1.65%
|
$1,427,886
$18.89 P/Share
|
|
Nov 03
2017
|
Celgene Corp /De/ > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
22,759
-0.47%
|
$432,421
$19.1 P/Share
|